As a triple GLP-1/GIP/glucagon receptor agonist, it adds glucagon receptor activation on top of the dual mechanisms that tirzepatide already provides
Is BPC-157 approved by health authorities
Which Peptides Are Now Available for Compounding
As a modified fragment of human growth hormone (hGH), this peptide focuses on fat metabolism without the typical side effects associated with full hGH therapy, such as insulin resistance or increased IGF-1 levels
Combined with Dihexa's synaptogenesis, this creates a dual-layer approach: build new connections and protect the cells that house them
As a triple receptor agonist targeting GIP, GLP-1, and glucagon pathways simultaneously, it differs structurally and mechanistically from earlier weight management peptides